why choose us

First received: December 09, 2022

Clinical Trial: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous ?? T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Glioblastoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous ?? T Cells (DeltEx)

Brief Summary: This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ).If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.

Read more